Astellas Pharma Reports Extraordinary Losses in Non-Consolidated Financial Results

Story Highlights
Astellas Pharma Reports Extraordinary Losses in Non-Consolidated Financial Results

Astellas Pharma ( (JP:4503) ) has provided an announcement.

Astellas Pharma reported extraordinary losses of JPY 60.6 billion in its non-consolidated financial results for Q3 of fiscal year 2024, due to a significant decline in the value of shares of its subsidiary, Ganymed Pharmaceuticals GmbH. However, this loss did not affect the company’s consolidated financial results as it was offset in the consolidated statements.

More about Astellas Pharma

Astellas is a global life sciences company focused on innovative therapies in oncology, ophthalmology, urology, immunology, and women’s health. The company is dedicated to developing healthcare solutions for diseases with high unmet medical needs through its research and development programs.

YTD Price Performance: -2.89%

Average Trading Volume: 5,625

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $17.08B

Find detailed analytics on 4503 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App